Jun 28, 2025, 15:50

DoD FY25 Breast Cancer Research Program Clinical Research Extension Award

The FY25 BCRP Clinical Research Extension Award funds projects that extend or expand data collection, patient follow-up, and analysis of existing breast cancer clinical studies—maximizing the impact of participant contributions and addressing knowledge gaps from early trial termination or limited follow-up.

Eligibility Criteria:

Applicant Organizations: Extramural and intramural entities (academic institutions, biotech companies, foundations, DOD labs, etc.), U.S. or foreign, for-profit or non-profit .
Principal Investigator: Independent investigators at any academic level (or equivalent) may serve as PI, Initiating PI, or Partnering PI. Applications may include up to two PIs under the Partnering PI Option (PPIO) .
Team Requirements: Research teams must include at least two breast cancer consumer advocates actively involved in advocacy organizations .
Research Scope: Supports hypothesis-testing or -generating correlative studies, molecular analyses, biomarker validation, or extended clinical follow-up of open, ongoing, or completed trials. Initiation of new clinical trials is not permitted .
Overarching Challenges: All applications must address at least one FY25 BCRP Overarching Challenge (e.g., preventing metastasis, overcoming overtreatment) unless justified otherwise .
Cost Sharing: Not required.

Funding Details:

Total Pool: Approximately 8.4 M USD to fund one award.
Budget Caps: Up to 7 M USD total costs for a single PI; up to 8.4 M USD combined for PPIO applications, over a maximum four-year period. Funds expire September 30, 2031; awards activate no later than September 30, 2026.
Allowable Costs: Direct and indirect costs per negotiated rates; personnel; supplies; equipment; travel (including multi-institutional collaboration support and consumer advocate participation); data sharing infrastructure; no clinical trial initiation costs.

Deadlines:

Letter of Intent (Pre-Application): August 27, 2025, by 5:00 p.m. ET
Full Application: September 10, 2025, by 11:59 p.m. ET
End of Verification Period: September 15, 2025, by 5:00 p.m. ET
Peer Review: November 2025
Programmatic Review: January 2026

Where to Go for Further Information & Application:

eBRAP Portal (pre-application & intramural)
Grants.gov Workspace (extramural full application): search Funding Opportunity Number HT942525BCRPCREA2
Program Announcement

BCRP Breast Cancer cancer CDMRP clinical-extension consumer-advocacy data collection eBRAP Grants.gov OncoDaily Oncology patient-follow-up translational research

25 Posts Not To Miss From ESMO GI 2025

Botensilimab and Balstilimab Show Durable Survival in MSS Colorectal Cancer: ESMO GI 2025 Update

Julian McMahon Dies at 56: A Look Back at His Private Cancer Battle and Legendary Acting Career

Vivek Subbiah: It’s Time We Evolve WHO Cancer Classification

ESMO 50th Anniversary: Half a Century of Evidence-Based Cancer Care